EU Regulation 2017/745 — the Medical Devices Regulation — has been described as transitional for years. The reality in 2026 is that the transition is over for most device categories. For medical device companies still treating MDR labeling compliance as a future concern, that framing is now a liability.
EUDAMED's UDI/device module was declared functional by the European Commission in November 2025. Under the transitional rules established by Regulation (EU) 2024/1860, mandatory use of that module takes effect as of May 28, 2026. For companies placing new devices on the EU market after that date, registration in EUDAMED must be completed before market placement, not alongside it.
EU MDR Annex I Chapter III sets out labeling requirements in detail. The key changes from the previous directives that device companies most commonly mishandle in practice:
The medical device symbol, indicating the product is a medical device, must appear on the device itself and on all levels of packaging. This is mandatory, not optional.
UDI (Unique Device Identification) must be present in two forms: machine-readable AIDC (automated identification and data capture) and human-readable HRI. A common mistake cited in MDR audit findings is mismatching UDI information across device and higher packaging levels. MDR requires full consistency, meaning every packaging layer must carry a UDI carrier that enables traceability throughout distribution.
Labels must be in the official language or languages of each EU member state where the device is marketed. Language localization enforcement across EU member states was identified as an increasing focus for notified body audits in 2026.
ISO 15223-1:2021 symbols are accepted under MDR for conveying standard information. Where symbols are used in regions where they are not recognized, a written explanation must accompany the device.
Non-compliant labeling under MDR can result in CE marking delays, notified body observations, product recalls, field safety corrective actions, or market withdrawal. These aren't theoretical risks — they are the documented consequences of labeling non-conformities in MDR audits.
Labeling-related non-conformities are among the most frequently reported issues during MDR audits. The errors showing up most consistently in practice are consistency errors: UDI information that matches correctly in one packaging context but not another; label updates applied in one language version but not propagated to others; symbol sets updated in the master template but not in the production artwork file. Every one of these error types shares a root cause: the final label was not compared systematically against the approved master before release.
If your device labels haven't been audited against current MDR requirements — specifically against the Annex I Chapter III checklist, UDI formatting requirements, and your per-market language obligations — that audit needs to happen before your next submission. And before any label update goes to print, a documented comparison against the approved master should be a mandatory step in the release process.
MDR compliance is not a destination. Label content changes, language requirements evolve, symbol standards update. The process needs to be built for ongoing verification, not one-time sign-off.